Table 3.
Patient no. | Gender | Age of onset | Clinical presentation | Citrulline levels (μmol/L)a | Blood ammonia (μmol/L)b | Mutaion 1 | Mutaion 2 | Outcome | Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Location | c.DNAc | Protein | Location | c.DNA | Protien | ||||||||
1 | Male | 3 y | Mild form | 90.05 | 70 | Intron 11 | c.773 + 4A > C | Intron 11 | c.773 + 4A > C | Well | This study | ||
2 | n.a. | 2 d | Neonatal form | 487.69 | 286 | Exon 6 | c.380G > A | p.Arg127Gln | Exon 6 | c.380G > A | p.Arg127Gln | Died | [12] |
3 | Male | n.p. | Mild form | 961.42 | 91 | Intron 4 | c.174 + 1G > A | Exon 7 | c.422 T > C | p.Val141Gly | Well | [13] | |
4 | Female | 4 d | Neonatal form | 1085.41 | 231 | Intron 11 | c.773 + 1G > A | Exon 12 | c.793C > T | p.Arg265Cys | Moderate | [13] | |
5 | Female | 3 m | Late-onset form | n.a. | 311 | Exon 7 | c.431C > G | p.Pro144Arg | Exon 14 | c.1087C > T | p.Arg363Trp | Moderate | [17] |
6 | Male | n.p. | Mild form | 111.21 | 17 | Exon 3 | c.53C > T | p.Ser18Leu | Exon 15 | c.1168G > A | p.Gly390Arg | Well | [16] |
7 | Female | 1 y, 3 m | Late-onset form | 928.77 | 160 | Exon 13 | c.847G > A | p.Glu283Lys | Exon 14 | c.1009 T > C | p.Cys337Arg | Moderate | [10] |
8 | Female | 1 y, 5 m | Late-onset form | 653 | 126 | Exon 5 | c.236C > T | p.Ser79Phe | Exon 7 | c.431C > G | p.Pro144Arg | n.a. | [14] |
9 | Female | 2 d | Neonatal form | 1577.7 | 670 | Exon 13 | c.951delT | p.F317LfsX375 | Exon 14 | c.1087C > T | p.Arg363Trp | Died | [11] |
10 | Male | 2 d | Neonatal form | 2513.5 | n.a. | Exon 13 | c.970G > A | p.Gly324Ser | Exon 13 | c.970G > A | p.Gly324Ser | n.a. | [15] |
aReference range: 5.5–30 μmol/L; b Reference range: 10–47 μmol/L; c novel mutations are in bold character
n.p. not present, n.a. not available, d day, y year